恒瑞医药(600276.SH)子公司注射用SHR-1826纳入突破性治疗品种名单

Core Viewpoint - Heng Rui Medicine (600276.SH) announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has had its injectable SHR-1826 included in the list of breakthrough therapies by the National Medical Products Administration's Drug Evaluation Center [1] Group 1 - The indication for SHR-1826 is proposed for monotherapy in patients with locally advanced or metastatic non-squamous non-small cell lung cancer who have failed at least one line of systemic therapy and have c-Met overexpression (2-3+, ≥50%) [1]